Detailed explanation of the usage guide for the new drug pemetinib for cholangiocarcinoma

Pemetinib, a targeted drug for specific patients with cholangiocarcinoma, brings new hope to adult patients with advanced, metastatic or inoperable cholangiocarcinoma who have FGFR2 fusion or rearrangement after systemic treatment. Its unique mechanism lies in its ability to precisely inhibit the activity of fibroblast growth factor receptor (FGFR), thereby effectively curbing the growth and spread of tumors. However, in order to ensure the therapeutic effect and patient safety, the correct medication method and precautions cannot be ignored.

1. Recommended medication methods

1. Standard dosage: 13.5mg per day, single dose, 21 days is a complete treatment cycle. The drug was taken continuously for the first 14 days and then stopped for 7 days.

2. How to take the medicine: Swallow the tablet whole, with or without food, but avoid chewing, splitting or dissolving the tablet.

3. Dose adjustment: For patients with severely impaired renal or liver function, it is recommended to adjust the daily dose to 9mg.

2. Key usage reminders

1. Side effects observation: Pemetinib may cause side effects such as diarrhea, nausea, and skin reactions. Patients should pay close attention to physical changes and seek medical attention promptly if severe discomfort occurs.

2. Pay attention to drug interactions: Pemetinib may interact with certain drugs, especially strongCYP3A inducers. Before starting treatment, patients should inform their doctor in detail about their medication history.

3. Use by special groups: Pregnant women, lactating women, and women who are planning to have children should avoid using pemetinib because it may cause potential risks to the fetus or newborn.

4. Adjust the dosage according to the doctor's instructions: The doctor will adjust the dosage according to the patient's specific situation and drug response. Patients should strictly follow the doctor's instructions and cannot make changes on their own.

5. Key points for drug storage: Pemetinib should be stored in a dark, dry and ventilated environment at room temperature (15°C-30°C) to ensure drug quality.

In summary, pemetinib provides a new treatment strategy for patients with cholangiocarcinoma, but correct administration and compliance with relevant precautions are equally important. Patients should maintain close communication with their medical team to ensure the safety and effectiveness of treatment.